Podcasts about Torque

Torque & Thrust Talk Show EP.40This Week We Talk About October 2025 Aviation, Gaming, and Automotive News! Plus Discuss Our Favorite Halloween Candy and Traditions!Like, Subscribe and Turn On Notifications!Join Our Discord | https://discord.gg/Fu7bBJHXgXFollow Us On BlueSky | https://bsky.app/profile/torqueandthrustts.bsky.socialFollow Us On Twitch | https://www.twitch.tv/torqueandthrusttalkshowFollow Us On Facebook | https://www.facebook.com/profile.php?id=61570628790833

A quiet Sunday turned into something else entirely. We kick things off with the Big Ten pulse check—Ohio State's defense looks nasty, disciplined, and deceptively complex, while Michigan's power run game still feels one note against an elite unit. Indiana's surprising charge raises a real question: are we watching a true new contender or a hot streak built on timing and grit? We dig into coaching impact, road-game confidence, and the thin margin between swagger and a trap.Then the night flips. A college party swells behind the house, cars creep onto the lawn, and a sick-to-your-stomach moment breaks out as the crowd surges into the yard. What follows is a case study in boundaries and tone: we ask, we wait, we de-escalate, and when it spikes again, we make the call. No theatrics, no heroics—just calm language, cool officers, and the party dissolving back to its side of the alley. It's part funny, part frustrating, and fully real life.We also take you on the road to a Dayton-area wedding where the dance floor never cools, late-night tracks get spicy, and the bride's joy becomes the best kind of chaos. In the quieter moments, we play with AI that turns our photos into Simpsons and Family Guy art—nostalgia in a click, proof that small creative toys can brighten a long day. And because comfort culture never sleeps, we drift into movies (Torque's underrated soundtrack and stunts, Depp's moody Sweeney Todd and Dark Shadows) and the most passionate debate of all: cereals. From Cinnamon Toast Crunch to the off-brand boxes you swear existed, we chase memories down every aisle.There's a final nudge on health and habits—less salt, more water, and a reminder that a second chance deserves a better routine. If you're here for sports, stories, tech toys, or just a laugh at midnight mayhem, you'll feel at home. If this ride hits, follow the show, share it with a friend, and drop us your wildest neighbor story or your Big Ten power ranking in the comments. We're listening.Send us a text message and let us know how awesome we are! (Click the link)!Support the show'Beavis and Butt-head' Cover art created by Joe Crawford

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

Torque & Thrust Talk Show EP.38Today We Discuss Our Favorite Types Of Vacations!Like, Subscribe and Turn On Notifications!Join Our Discord | https://discord.gg/Fu7bBJHXgXFollow Us On BlueSky | https://bsky.app/profile/torqueandthrustts.bsky.socialFollow Us On Twitch | https://www.twitch.tv/torqueandthrusttalkshowFollow Us On Facebook | https://www.facebook.com/profile.php?id=61570628790833

Torque & Thrust Talk Show EP.39We Are Back!Like, Subscribe and Turn On Notifications!Join Our Discord | https://discord.gg/Fu7bBJHXgXFollow Us On BlueSky | https://bsky.app/profile/torqueandthrustts.bsky.socialFollow Us On Twitch | https://www.twitch.tv/torqueandthrusttalkshowFollow Us On Facebook | https://www.facebook.com/profile.php?id=61570628790833

Dopo la base aerobica del Mesociclo 1, saliamo di piano.Nel Mesociclo 2 (4 settimane) portiamo in bici la forza costruita off-bike e introduciamo la soglia in modo sostenibile.Dentro l'episodio:Perché “torque” (bassa cadenza): forza specifica sul gesto → 1–2' a bassa rpm, alto carico sui pedali, coinvolgi le fibre veloci già stimolate in palestraSFR? Concetto simile, ma “torque” è più chiaro e misurabile per evitare confusione.Soglia Z4 con ripetute brevi (4–6'): stessa dose efficace di lavoro totale, ma più sostenibile (meno stress, più aderenza).Progressione intelligente: mantieni un filo di HI senza bruciarti; il volume “pesante” verrà nei blocchi successivi.Settimana tipo: feriali = sedute brevi e specifiche; weekend = volume consapevole.Pensato per amatori over 45 → forza che cala e recupero più lungo richiedono scelte mirate

Matthew Crawley speaks with Barnie and Callum from Captain Morrow and the Sands of Time, a new production over at Q Theatre. Then, Silver Scroll 2025 finalists Mazbou Q and Ch! Nonso are on the line to discuss their nominated track Torque. Later, Fables is in the studio to talk about her recently announced debut album and new track Sundown. Whakarongo mai nei! Thanks to The Beer Spot

Director of Golf Performance and Innovation at Dick's Sporting Goods and Golf Galaxy Chris Marchini returns to answer your questions with Uncle Gene. Plus, a JWall giveaway spree. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A huge thank you to CircleDspecialties for shooting this video with us! Contact Circle D here:Website: circledspecialties.comFacebook: facebook.com/circleDspecialtiesEmail: sales@circledspecialties.comPhone: (713) 895-8834

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

Send us a textWill Chinese cars dominate the UK?

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

In this episode, Rick speaks with Lee Hodges of Torque Fitness. Torque was the Alloy vendor of the year last year and continues to be the sole provider of equipment for the Alloy franchise.They discuss the powerful blend of aesthetics, functionality, and foresight that makes Torque the go-to provider for Alloy Personal Training.Lee shares how his nearly 30 years in the fitness industry and his passion for strength training led him to Torque, where design isn't just about equipment -- it's about experience.The Torque approach is listening first, designing around client goals, and crafting space-efficient setups that look as good as they perform.Whether it's kettlebells or the multifunctional Racks, Torque's products are tailored for real-world training and long-term durability.Rick and Lee also look ahead to what's next: the integration of recovery tools, the enduring rise of strength training, and how drugs like GLP-1s may shift the focus from cardio to muscle preservation.Tune in to learn more!Key TakeawaysIntro (00:00)Lee Hodges' Professional Background (02:05)Transition to Torque and Philosophy (03:55)Torque's Unique Products and Design Philosophy (06:24)Torque's Process and Customer Service (11:29)Challenges and Solutions in the Fitness Industry (12:56)Future Trends and Industry Insights (13:08)Final Thoughts and Contact Information (28:14)Additional Resources:- Torque Fitness: https://www.torquefitness.com/—- Alloy Personal Training- Learn About The Alloy Franchise Opportunity---------You can find the podcast on Apple, Google, Spotify, Stitcher, or wherever you listen to podcasts.If you haven't already, please rate and review the podcast on Apple Podcasts!

The Aubrey Masango Show is presented by late night radio broadcaster Aubrey Masango. Aubrey hosts in-depth interviews on controversial political issues and chats to experts offering life advice and guidance in areas of psychology, personal finance and more. All Aubrey’s interviews are podcasted for you to catch-up and listen. Thank you for listening to this podcast from The Aubrey Masango Show. Listen live on weekdays between 20:00 and 24:00 (SA Time) to The Aubrey Masango Show broadcast on 702 https://buff.ly/gk3y0Kj and on CapeTalk between 20:00 and 21:00 (SA Time) https://buff.ly/NnFM3Nk Find out more about the show here https://buff.ly/lzyKCv0 and get all the catch-up podcasts https://buff.ly/rT6znsn Subscribe to the 702 and CapeTalk Daily and Weekly Newsletters https://buff.ly/v5mfet Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

Back, by popular demand, with my updated top zero torque putter list! Here are my top 10 favorite putters that are balanced for the face to point towards the target. Here are my favorites for 2025!

Join us for an epic dive into the world of Jeep mods, tire maintenance, and cutting-edge gimbal tech with a Greg Henderson original! In this video, we uncover the story behind a unique Jeep antenna decoration that sparked a viral moment, explore why you should always buy five tires for your off-road rig, and showcase an affordable $29 Amazon gimbal that tracks you flawlessly without needing an app. From tire rotation tips to avoid uneven wear to the physics of balance beads and why humidity can ruin them, this video is packed with practical advice for Jeep enthusiasts and off-roaders. Plus, we dive into torque wrench etiquette, the dangers of over-torquing lug nuts, and why anti-seize is a must for beadlock bolts. Don't miss the hilarious banter and expert insights from Greg and the crew!

Wes Robertson outlines the launch of LT Games at the Target Center in Minneapolis on October 25–26. He walks through the 17-station format including machine runs, barbell and dumbbell work, wall balls, box jump-overs, ski and row segments, with a choose-your-own-adventure loading system to hit total weight targets. We cover judging, heat structure, equipment from Torque, the expected field size of around 250 athletes, and Lifetime's long-term plan for more hubs, qualifiers, and eventually a national championship. Hugo Inglis (Olympic hockey, High Impact Athletes) explains how his Rio Olympic experience led to founding High Impact Athletes, an athlete-led movement connecting pros and now HYROX racers to vetted global charities. He details how Race for Impact works inside HYROX ticketing, how charities are selected by independent evaluators, and the current focus areas: global health, mental health, climate solutions, and women's empowerment, or animal welfare. Guest Links: LT Games | Race For Impact Listen on Apple or Spotify Support us through The Cup Of Coffee Follow Hybrid Fitness Media on IG Watch On YouTube    

Welcome to another flagship episode of the Jeep Talk Show!

Major parcel carriers like UPS and DHL are hiking surcharges ahead of the holiday season, with UPS adding fees for residential services, next-day air, oversized packages, and high-volume shippers starting September 8th. These increases, which follow earlier announcements from FedEx and UPS, are designed to ensure operational reliability through January 17th. In a significant legal development, a federal court has ruled most of President Trump's tariffs illegal, finding that the emergency law he used did not grant him authority to levy them in a 7-4 decision. This decision could impact tariffs on China, Canada, and Mexico, though they will remain in place through October 14th to allow for an appeal to the US Supreme Court. In trucking technology, Torque Robotics has partnered with Edge Case Research to develop robust safety cases for Level 4 autonomous trucks, with Edge independently assessing Torque's driverless safety framework. This collaboration supports Torque's commitment to safety and independent validation, aiming to launch fully autonomous long-haul trucks in the U.S. by 2027. Don't miss today's FreightWaves TV programming, including a new episode of Check Call with Mary O'Connell at 12:30, followed by Loaded and Rolling with Thomas Wason at 2 PM. Also, remember to register for the upcoming F3 event at live.freightwaves.com and use the code MORNINGMINUTEF325 to save up to $900 on your ticket. Learn more about your ad choices. Visit megaphone.fm/adchoices

Major parcel carriers like UPS and DHL are hiking surcharges ahead of the holiday season, with UPS adding fees for residential services, next-day air, oversized packages, and high-volume shippers starting September 8th. These increases, which follow earlier announcements from FedEx and UPS, are designed to ensure operational reliability through January 17th. In a significant legal development, a federal court has ruled most of President Trump's tariffs illegal, finding that the emergency law he used did not grant him authority to levy them in a 7-4 decision. This decision could impact tariffs on China, Canada, and Mexico, though they will remain in place through October 14th to allow for an appeal to the US Supreme Court. In trucking technology, Torque Robotics has partnered with Edge Case Research to develop robust safety cases for Level 4 autonomous trucks, with Edge independently assessing Torque's driverless safety framework. This collaboration supports Torque's commitment to safety and independent validation, aiming to launch fully autonomous long-haul trucks in the U.S. by 2027. Don't miss today's FreightWaves TV programming, including a new episode of Check Call with Mary O'Connell at 12:30, followed by Loaded and Rolling with Thomas Wason at 2 PM. Also, remember to register for the upcoming F3 event at live.freightwaves.com and use the code MORNINGMINUTEF325 to save up to $900 on your ticket. Learn more about your ad choices. Visit megaphone.fm/adchoices

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

It's the 11th running of the Race For the Future in Fort Worth, TX on September 14, 2025. This is YOUR chance to make a difference in a industry we all love so much. Important links: All the money goes to The Foundation For Dental Laboratory Technology: https://dentallabfoundation.org/ All about the Race: https://dentallabfoundation.org/news-events/race-for-the-future/ Race website: https://fortworth.californiatriathlon.org/ TO DONATE: https://fdlt.memberclicks.net/donor-form#/ Select: Race for the Future Enter the name of the racer you want to support: BARB WARNER or THE CROWN JEWELS Enter the amount (One Million Dollars) Full Arch Immediate Load Hybrids is still one of the most profitable restorations to a lab. The skill and confidence to do them is difficult, but thanks to Dr. Brandon Kofford, the day of surgery is getting even easier. Two years ago, Dr. Kofford came on this podcast to talk about Smart Denture Conversion. The workflow to make a faster and better converted denture. Well after a lot of work and FDA planning, they are back as Smart on X and have introduced the Omibut (https://smartonx.com/pages/omnibut), a new MUA that can be used at any angle. He also talks about improving the original version to make Smart Denture Conversion 2.0 (https://smartonx.com/collections/smart-denture-conversions-kits/products/pre-coated-tibase-recharge-kit)and the use of prefabricated arches (https://smartonx.com/pages/rapid-arches). Let's be honest. There are a LOT of zirconia on the market these days. How do you know which is which? Is one better than another? Is there one that can handle every situation? Check out a FREE webinar from Ivoclar (https://www.ivoclar.com/en_us) called Zirconia Unboxed with Jeff Smith, CDT. (https://www.ivoclar.com/en_us/course/zirconia-unboxed/246115?utm_source=External+-+Voice+from+the+Bench&utm_medium=QR+code&utm_campaign=Academy&utm_term=August) "This introductory webinar is the first in a five-part series designed to address the most frequently asked questions by dental labs when selecting zirconia for their restorations. With a focus on practical guidance, this session explores the key considerations in choosing the right zirconia, including material properties, esthetics, and processing techniques. This introductory webinar is the first in a five-part series designed to address the most frequently asked questions by dental labs when selecting zirconia for their restorations. With a focus on practical guidance, this session explores the key considerations in choosing the right zirconia, including material properties, esthetics, and processing techniques." Check it out at: https://www.ivoclar.com/enus/course/zirconia-unboxed/246115?utmsource=External+-+Voice+from+the+Bench&utmmedium=QR+code&utmcampaign=Academy&utm_term=August Special Guest: Dr. Brandon Kofford.

Welcome to the Episode 118 Highlights Show of the Trail Running Ireland Podcast sponsored by EcoTrail Wicklow 2025.In last weeks show we had a super training topic with René Borg from Running Coach Ireland to chat through: Low Torque and High Torque and Torque here refers to the muscular force per stride as we move through the trails.It's a very interesting lens to better understand what's really happening in our bodies during different types of training. Let´s discuss.Everyone, get your running gear on, lets go.https://wicklow.ecotrail.com

Dr. Erik Henrikson, PING Director of Golf Science, joins Marty Jertson in the PING Putting Lab for a discussion on putter torque and why it's a popular topic in golf. They cover the five senses and physics of putting, putter innovation, and the latest PLD Milled SE model, the Ally Blue Onset. See omnystudio.com/listener for privacy information.

In this episode of Fits with the Founder, Nick Sherburne and Brad Syslo tee up a packed lineup for golf lovers. They count down the Top 5 golf courses in Chicago, share must-know tips on golf course etiquette (yes, fixing ball marks matters), and take a deep dive into loft and lie adjustments—revealing how small tweaks can save you strokes. Then, special guest Matt Saternus of PluggedIn Golf joins to bust every myth about zero torque putters. Whether you're a weekend golfer or a gear junkie, this one's a hole-in-one.

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

Welcome to Episode 118 of the Trail Running Ireland Podcast sponsored by EcoTrail Wicklow 2025.In this weeks show we've a super training topic with René Borg from Running Coach Ireland to chat through: Low Torque and High Torque and Torque here refers to the muscular force per stride as we move through the trails.It's a very interesting lens to better understand what's really happening in our bodies during different types of training. Let´s discuss.Everyone, get your running gear on, lets go.https://wicklow.ecotrail.com

In this episode, Chad sits down with Francis Hopping from Corning Ford, and they get into one thing we all care about...Trucks. From engine packages to suspensions, towing setups to tech features, they break down what really matters when you're buying your next rig and why Corning Ford is the #1 Super Duty dealer in the country. If you've ever wondered which truck fits your lifestyle, this one will help you dial it in. But it's not all specs and horsepower. Chad and Francis talk DEF, road trips, life, golf, fishing, and everything in between. This episode's all about what makes the Corning Ford family something we're proud to be a part of. If you love trucks and good conversation, you'll be all in on this one. This episode is brought to you by Corning Ford, LEER Truck Toppers, Mickey Thomoson Tires and Wheels, RIGID Industries LED, BedSlide, Bodyguard Bumpers, California Waterfowl Association, And, Oakley Sunglasses.

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

In this episode, we sit down with one of the brightest young talents in professional cycling — Valentin Paret-Peintre. At just 24, he's already claimed stage victories at the Giro d'Italia, the Tour of Oman, and made history as the fifth Frenchman ever to win atop Mont Ventoux during his maiden Tour de France.Join us for a relaxed and insightful conversation recorded during pre-season camp, as Valentin opens up about life with Soudal Quick-Step, his favorite alpine climbs, his power-to-weight secrets, and how growing up in a cycling-obsessed family shaped his journey.If you're a fan of the high mountains, French alpine gems, and the inner mindset of a pure climber – this one's for you!The interview was recorded as a friendly chat at the beginning of the season, following a product feedback session. – LINKS –Valentin Paret-Peintre Host: ⁠⁠⁠⁠⁠Soren Jensen⁠⁠⁠⁠⁠ Climbs:Col de l'Arpettaz (Ugine)Col de la Colombiere (Cluses)Col des Aravis (Flumet)Mont-Salève– CHAPTERS –00:00 – Quickfire intro00:39 – Welcome & Valentin's rise: Giro stage win to Ventoux glory01:45 – Riding with the Wolfpack: New chapter with Soudal Quick-Step03:13 – Settling in with the team & first impressions from training camp04:35 – Why the Giro d'Italia is his favorite Grand Tour05:39 – Growing up in Haute-Savoie & descending skills06:49 – Favorite local climb: Col de la Colombière08:08 – Riding for joy, peace & scenery — not always for coffee09:40 – Reflections on mountain solitude & wild landscapes10:51 – Hidden gem climbs: Col de l'Arpettaz and others11:49 – What makes a world-class climber: More than just numbers13:27 – Beating personal records at the Giro & Tour de Suisse15:21 – In-the-saddle vs out-of-saddle: His climbing technique16:09 – Bodyweight, gym work & nutrition18:06 – Training efforts: Torque work, over/unders, and VO2 sets20:32 – Training solo vs in groups & life in Chambéry22:11 – Annual New Year's ride around Lac Léman tradition22:58 – Aero obsession: Race suits vs jersey/shorts24:23 – Castelli product insights & racing with innovation25:21 – First impressions of the Sanremo S8 race suit26:16 – Why he joined Soudal Quick-Step & learning from Remco & Landa29:51 – Not ready to lead just yet — embracing a support role31:51 – Eyeing the Tour de France debut in 202533:02 – On racing the Tour as a French rider: Personal dream34:06 – Favorite Tour climb: Col du Galibier and its magic36:08 – Favorite off-season meal? Spaghetti alla bolognese

Visionary director Joseph Kahn (DETENTION, BODIED, TORQUE) joins Adam and Joe in the ArieScope studio to discuss his incredible career journey and the making of his new film ICK (in theaters now). From learning how to speak the language of cinema in the 80's thanks to Spielberg films and MTV… to how a fake company name and a briefcase led to him becoming one of the greatest music video directors in history working with artists like TAYLOR SWIFT, KORN, MUSE, BRITNEY SPEARS, PUBLIC ENEMY, ROB ZOMBIE, and more… to the trials of making his first feature TORQUE and his creative redemption with DETENTION and BODIED… to how he's broken down filmmaking into “science” and “language” and his theory of “5th Dimensional edits”… to the making of his new movie ICK and why it's all still “a struggle”, whether its a Taylor Swift video or his latest feature film… this amazing, no f's given conversation with one of the signature visual voices in pop-culture has been a long time coming! Don't miss a minute of YORKIETHON 9 happening THIS coming weekend (July 25th - 27th)! THE MOVIE CRYPT's 9th annual live marathon to benefit Save A Yorkie Rescue can be watched FREE on www.ariescope.com or www.bloody-disgusting.com!

Max is joined is joined by friend and co-host of The Waffle Press podcast, Diego Crespo to chat with director Joseph Kahn and returning guest and friend of the show Chancler Haynes on their new movie ICK, playing this weekend from the 27th-29th of July for FATHOM Events. They go in on their love of Kahn's first feature, TORQUE, as well as their historic work in the music video industry alongside names like Beyonce, Taylor Swift, and many more.Find Us on these Platforms:Guest- Chancellor Haynes: Twitter/Instagram/IMDB/Cosmostreet https://x.com/ChanclerHaynes https://www.instagram.com/chancler/?hl=en https://www.imdb.com/name/nm4016426/ https://cosmostreet.com/editors/cosmo-street/chancler-haynes/general-reel/Joseph Kahn: Twitter/IMDB/Instagtram/JosephKahn.com https://x.com/josephkahn?lang=en https://www.imdb.com/name/nm0994538/ https://www.instagram.com/josephkahn/https://www.josephkahn.comThe Boys-Action For Everyone: Twitter/BlueSky/Twitch/Instagram https://x.com/A4EPodcast https://bsky.app/profile/a4epodcast.bsky.social https://www.twitch.tv/action4everyone https://www.instagram.com/a4epodcast/Michael Scott: BlueSky- https://bsky.app/profile/hibachijustice.bsky.socialVyceVictus: Twitter/BlueSky/Instagram/Letterboxd- https://x.com/VyceVictus https://bsky.app/profile/vycevictus.bsky.social https://www.instagram.com/vycevictus/ https://letterboxd.com/vycevictus/ Liam O'Donnell: Twitter/Instagram- https://x.com/LiamODin https://www.instagram.com/liamodin/?hl=enMax Deering: Twitter/Bluesky/Letterboxd/Polygon- https://x.com/ODSTSpartan https://bsky.app/profile/odstspartan.bsky.social https://letterboxd.com/ODSTSpartan/https://www.polygon.com/horror/562913/sinners-black-vampire-movies-list-watchhttps://www.neonsplatter.com/editorials/the-neon-splatter-interview-micho-rutare-of-predator-killer-of-killers

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

Tommy Fleetwood Choked on ANOTHER possible victory. Inside Keagan's Winning Bag and why YOU should Play Srixon Irons. Who won the Torqueless Putter Test and who is everyone using Striped golf balls? Cozy Earth 40% off: NOPUTTS https://cozyearth.com/?nbt=nb%3Aadwords%3Ag%3A17064266580%3A134481050765%3A599242160877&nb_adtype=&nb_kwd=cozy%20earth&nb_ti=kwd-499167107192&nb_mi=&nb_pc=&nb_pi=&nb_ppi=&nb_placement=&nb_li_ms=&nb_lp_ms=&nb_fii=&nb_ap=&nb_mt=e&tw_source=google&tw_adid=599242160877&tw_campaign=17064266580&tw_kwdid=kwd-499167107192&gad_source=1&gad_campaignid=17064266580&gbraid=0AAAAADnxV9S7POlJriFYygUNlPS0vr3yC&gclid=CjwKCAjwvO7CBhAqEiwA9q2YJSQ3xpj6iCSrrz_dTY0ScdUGAFQe_riOkt43TnjkuMzukW3rSdX8RRoCqIQQAvD_BwE 00:00 Welcome 02:35 Tommy Fleetwood Choked 06:35 What's in Keegan's Bag? 12:06 Zero Torque Results 31:01 More Striped Golf Balls 38:32 Japanese Irons

Torque-angle curve of the knee flexors in athletes with a prior history of hamstring strain Mikami K, Samukawa M, Oba K, et al. Phys Ther Sport. 2022;54:29-35. doi:10.1016/j.ptsp.2021.11.008 Due to copyright laws, unless the article is open source we cannot legally post the PDF on the website for the world to download at will. Brought to you by our sponsors at: CSMi – https://www.humacnorm.com/ptinquest Learn more about/Buy Erik/Jason/Chris's courses – The Science PT Support us on the Patreons! Music for PT Inquest: “The Science of Selling Yourself Short” by Less Than Jake Used by Permission Other Music by Kevin MacLeod – incompetech.com: MidRoll Promo – Mining by Moonlight Koal Challenge – Sam Roux

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

Send us a textThis is a fantastic discussion with filmmaker Joseph Kahn (DETENTION, BODIED, TORQUE, your fave music videos) about his very cool and funny new movie ICK. He also reflects on writing DETENTION with Mark, the realities of making indie films, and why being told you have "MTV style" doesn't land when you helped create MTV style. 

On this episode of The Adam and Dr. Drew Show, Adam and Dr. Drew try to pinpoint the moment society began its slow descent into chaos. They dive into the cultural obsession with “work-life balance” and call out modern men who think more like chicks than dudes. The two also react to a recent Gavin Newsom tweet and discuss the absurdity of today's car commercials—including a Volkswagen ad featuring two men caring for a sheep like it's a dog, and another with a man writing a letter in his car. What happened to selling horsepower and performance? Their takeaway: this generation no longer sweats the details—and it shows.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This summer episode of Steel Stories brings you a series of fast-paced, thought-provoking conversations recorded live at the 2025 U. S. Steel Tubular Seminar in Fairfield, Alabama. From industry veterans to emerging leaders, we hear how technology, partnerships, and precision manufacturing are shaping the future of the tubular steel industry.

Don't forget to send us your questions or subject for future episodes.Subscribe/Follow, give us a rating and give us a follow on Instagram for all the latest Podcast news - https://www.instagram.com/drivetorque...Cheers and see you at the next one

In this episode of the HVAC Know It All Podcast, host Gary McCreadie continues his conversation with David Rames, Senior Product Manager at Midea America. In Part 2, David talks about the importance of pressure testing and evacuating each line set in multi-zone ductless systems. He emphasizes using a torque wrench to avoid over-tightening flare nuts, which can cause leaks. David also explains the dry mode feature in Midea systems, designed to control humidity effectively. The episode wraps up with advice on proper installation, maintenance, and the value of training to ensure quality work and satisfied customers. David Rames discusses the importance of pressure testing and evacuating each line set in multi-zone ductless systems. He explains how using a torque wrench can prevent over-tightening flare nuts, which can cause refrigerant leaks. David also highlights the dry mode feature in Midea systems, which helps manage humidity by slowing down the fan and cooling the room. The episode wraps up with advice on proper installation, leak testing, and the need for thorough training to ensure quality installs and satisfied customers. Throughout this episode, David talks about the steps to ensure a proper installation in multi-zone ductless systems. He explains the importance of pressure testing and evacuating each line set separately to avoid leaks. David also discusses the need for using a torque wrench to avoid over-tightening flare nuts. He highlights the dry mode feature in Midea systems, which helps control humidity. Lastly, he shares tips on doing thorough training and following manuals to get the best results on every job. Expect to Learn: Why is pressure testing and evacuating each line set crucial? How a torque wrench prevents over-tightening flare nuts. What the dry mode feature in Midea systems does for humidity control. The importance of following the installation manual for better results. Why thorough training ensures high-quality installs and satisfied customers. Episode Highlights: [00:00] - Intro to Part 02 with David Rames [01:33] - Key steps for pressure testing and evacuation [02:59] - Using a torque wrench the right way [05:36] - Manuals matter for a clean install [07:23] - Understanding torque ranges and flare fitting [09:25] - Leak testing tips and skipping filter dryers [10:56] - Doing evacuation and decay tests properly [13:56] - Good installs stop blaming on equipment [16:42] - Using dry mode for better humidity control [18:12] - How dry mode changes fan speed and coil temp [20:12] - When misuse, not installation, causes complaints [25:21] - Wrap-up and where to learn more about Midea

In this episode of Strength In Knowledge, we step off the mound and into the lab to explore a surprising connection: how lower body jump performance might predict elbow injuries in professional baseball pitchers. Based on the intriguing study by Mayberry, Mullen, and Murayama, we break down how biomechanics and asymmetries seen in jump tests could flag potential risks for UCL injuries.From kinetic chain theory to practical screening tools, we discuss the implications of this research for strength coaches, rehab specialists, and anyone involved in the performance care of throwing athletes. Could a vertical jump really tell you something about elbow health? Turns out—it might.⚾

Ever seen a 550whp front-wheel-drive Micra out on track?Sean Austin's FWD K11 Nissan Micra is running a turbocharged Primera P11 SR20VE+T Neo VVL (the best SR20?) & 6-speed gearbox, Haltech Nexus R3 engine/power distribution management, Haltech iC-7 dash, and enough power to torque steer into another dimension.Use the code ‘PODCAST500' to get $500 OFF HPA's VIP Package: https://hpcdmy.co/podvipWith help from CDI Motorsport, Raceworks, Knight Family Motorsport, and a front end swapped in from a Pulsar, this car has evolved from track beater to full track weapon at the World Time Attack Challenge. It's light, fast, and rowdy, but Sean's also realistic about its limitations, admitting the platform might have hit its ceiling. That said, not sure we believe that a project is ever truely 'finished'!This walkaround covers the build, from the engine setup and fabrication, through to suspension compromises and alignment headaches. It's a quick look at what it takes to extract big performance from an unlikely chassis, and believe it or not at this stage all for under $20,000 Kangaroo Dollars (AUD).#highperformanceacademy #BuildTuneDrive #laterk11 #noideaclub #SR20VVL #Micra #FWD #k11 #TimeAttack #Haltech #WTAC2 #learndriveoptimise #learntotune #enginebuilding101 #dontletthesmokeout #wiring101 #cars #motorsport #racing #boost 

Dr. John Sweetenham and Dr. Erika Hamilton highlight key abstracts that were presented at ASCO25, including advances in breast and pancreatic cancers as well as remarkable data from the use of structured exercise programs in cancer care. Transcript Dr. Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. Today, we'll be discussing some of the key advances and novel approaches in cancer care that were presented at the 2025 ASCO Annual Meeting. I'm delighted to be joined again by the chair of the Meeting's Scientific Program, Dr. Erika Hamilton. She is a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee.  Our full disclosures are available in the transcript of this episode. Dr. Hamilton, congratulations on a fantastic meeting. From the practice-changing science to the world-renowned speakers at this year's Meeting, ASCO25 really reflected the amazing progress we're seeing in oncology today and the enormous opportunities that lie ahead of us. And thanks for coming back on to the podcast today to discuss some of these advances. Dr. Hamilton: Thanks, Dr. Sweetenham. I'm happy to join you today. It really was an impactful ASCO Annual Meeting. I probably am biased, but some great research was presented this year, and I heard lots of great conversations happening while we were there. Dr. Sweetenham: Yeah, absolutely. There was a lot of buzz, as well as a lot of media buzz around the meeting this year, and I think that's probably a good place to start. So I'd like to dive into abstract number LBA3510. This was the CHALLENGE trial, which created a lot of buzz at the meeting and subsequently in the media. This is the study that was led by the NCI Canada Clinical Trials Group, which was the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer, which demonstrated that a post-treatment structured exercise program is both feasible and effective in improving disease-free survival in this patient group. The study was performed over a long period of time and in many respects is quite remarkable. So, I wonder if you could give us your thoughts about this study and whether you think that this means that our futures are going to be full of structured exercise programs for those patients who may benefit. Dr. Hamilton: It's a fantastic question. I think that this abstract did create a lot of buzz. We were very excited when we read it. It was highlighted in one of the Clinical Science Symposium sessions. But briefly, this was a phase 3 randomized trial. It was conducted at 55 centers, so really a broad experience, and patients that had resected colon cancer who completed adjuvant therapy were allowed to participate. There were essentially 2 groups: a structured exercise program, called ‘the exercise group,' or health education materials alone, so that was called just ‘the health education group.' And this was a 3-year intervention, so very high quality. The primary end point, as you mentioned, was disease-free survival. This actually accrued from 2009 to 2024, so quite a lift, and almost 900 patients underwent randomization to the exercise group or the health education group. And at almost 8 years of follow-up, we saw that the disease-free survival was significantly longer in the exercise group than the health education group. This was essentially 80.3% of patients were disease-free in exercise and 73.9% in the health education group. So a difference of over 6 percentage points, which, you know, at least in the breast cancer world, we make decisions about whether to do chemotherapy or not based on these kind of data. We also looked at overall survival in the exercise group and health education group, and the 8-year overall survival was 90.3% in the exercise group and 83.2% in the health education group. So this was a difference of 7.1%. Still statistically significant. I think this was really a fantastic effort over more than a decade at over 50 institutions with almost 900 patients, really done in a very systematic, high-intervention way that showed a fantastic result. Absolutely generalizable for patients with colon cancer. We have hints in other cancers that this is beneficial, and frankly, for our patients for other comorbidities, such as cardiovascular, etc., I really think that this is an abstract that deserved the press that it received. Dr. Sweetenham: Yeah, absolutely, and it is going to be very interesting, I think, over the next 2 or 3 years to see how much impact this particular study might have on programs across the country and across the world actually, in terms of what they do in this kind of adjuvant setting for structured exercise. Dr. Hamilton: Absolutely.  So let's move on to Abstract 3006. This was an NCI-led effort comparing genomic testing using ctDNA and tissue from patients with less common cancers who were enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. Tell us about your takeaways from this study. Dr. Sweetenham: Yeah, so I thought this was a really interesting study based, as you said, on NCI-MATCH. And many of the listeners will probably remember that the original NCI-MATCH study screened almost 6,000 patients to assess eligibility for those who had an actionable mutation. And it turned out that about 60% of the patients who went on to the study had less common tumors, which were defined as anything other than colon, rectum, breast, non–small cell lung cancer, or prostate cancer. And most of those patients lacked an eligible mutation of interest and so didn't get onto a trial therapy. But with a great deal of foresight, the study group had actually collected plasma samples from these patients so that they would have the opportunity to look at circulating tumor DNA profiles with the potential being that this might be another way for testing for clinically relevant mutations in some of these less common cancer types. So initially, they tested more than 2,000 patients, and to make a somewhat complicated story short, there was a subset of five histologies with a larger representation in terms of sample size. And these were cholangiocarcinoma, small cell lung cancer, esophageal cancer, pancreatic, and salivary gland cancer. And in those particular tumors, when they compared the ctDNA sequencing with the original tumor, there was a concordance there of around 84%, 85%. And in the presentation, the investigators go on to list the specific mutated genes that were identified in each of those tumors. But I think that the other compelling part of this study from my perspective was not just that concordance, which suggests that there's an opportunity there for the use of ctDNA instead of tumor biopsies in some of these situations, but what was also interesting was the fact that there were several clinically relevant mutations which were detected only in the circulating tumor DNA. And a couple of examples of those included IDH1 for cholangiocarcinoma, BRAF and p53 in several histologies, and microsatellite instability was most prevalent in small cell lung cancer in the ctDNA. So I think that what this demonstrates is that liquid biopsy is certainly a viable screening option for patients who are being assessed for matching for targeted therapies in clinical trials. The fact that some of these mutations were only seen in the ctDNA and not in the primary tumor specimen certainly suggests that there's some tumor heterogeneity. But I think that for me, the most compelling part of this study was the fact that many of these mutations were only picked up in the plasma. And so, as the authors concluded, they believe that a comprehensive gene profiling with circulating tumor DNA probably should be included as a primary screening modality in future trials of targeted therapy of this type. Dr. Hamilton: Yeah, I think that that's really interesting and mirrors a lot of data that we've been seeing. At least in breast cancer, you know, we still do a biopsy up front to make sure that our markers, we're still treating the right disease that we think we are. But it really speaks to the utility of using ctDNA for serial monitoring and the emergence of mutations. Dr. Sweetenham: Absolutely. And you mentioned breast cancer, and so I'd like to dwell on that for a moment here because obviously, there was a huge amount of exciting breast cancer data presented at the meeting this year. And in particular, I'd like to ask you about LBA1008, the DESTINY-Breast09 clinical trial, which I think has the potential to establish a new first-line standard of care for metastatic HER2+ breast cancer. And that's an area where we haven't seen a whole lot of innovation for around a decade now. So can you give us some of the highlights of this trial and what your thinking is, having seen the results? Dr. Hamilton: Yeah, absolutely. So this was a trial in the first-line metastatic HER2 setting. So this was looking at trastuzumab deruxtecan. We certainly have had no shortage of reports around this drug, initially approved for later lines. DESTINY-Breast03 brought it into our second-line setting for HER2+ disease and we're now looking at DESTINY-Breast09 in first-line. So this actually was a 3-arm trial where patients were randomized 1:1:1 against standard taxane/trastuzumab/pertuzumab in one arm; trastuzumab deruxtecan with pertuzumab in another arm; and then a third arm, trastuzumab deruxtecan alone. And what we did not see reported was that trastuzumab deruxtecan-alone arm. But we did have reports from the trastuzumab deruxtecan plus pertuzumab versus the chemo/trastuzumab/pertuzumab. And what we saw was a statistically significant improvement in median progression-free survival, 26.9 months up to 40.7, so an improvement of 13.8 months, over a year in PFS. Not to mention that we're now in the 40-month range for PFS in first-line disease. Really, across all subgroups, we really weren't able to pick out a subset of patients that did not benefit. We did see about a 12% ILD rate with trastuzumab deruxtecan. That really is on par with what we've seen in other studies, around 10%-15%. I think that this is going to become a new standard of care in the first-line. I think it did leave some unanswered questions. We saw some data from the PATINA trial this past San Antonio Breast, looking at the addition of endocrine therapy with or without a CDK4/6 inhibitor, palbociclib, for those patients that also have ER+ disease, after taxane has dropped out in the first-line setting. So how we're going to kind of merge all this together is, I suspect that there are going to be patients that we or they just don't have the appetite to continue 3 to 4 years of trastuzumab deruxtecan. And so we're probably going to be looking at a maintenance-type strategy for them, maybe integrating the PATINA data there. But how we really put this into practice in the first-line setting and if or when we think about de-escalating down from trastuzumab deruxtecan to antibody therapy are some lingering questions. Dr. Sweetenham: Okay, so certainly is going to influence practice, but watch this space for a little bit longer, it sounds as though that's what you're saying. Dr. Hamilton: Absolutely.  So let's move on to GI cancer. Abstract 4006 reported preliminary results from the randomized phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus the chemo gemcitabine/nab-paclitaxel alone in patients with previously untreated metastatic pancreatic cancer. Can you tell us more about this study? Dr. Sweetenham: Yeah, absolutely. As you mentioned, elraglusib is actually a first-in-class inhibitor of GSK3-beta, which has multiple potential actions in pancreatic cancer. But the drug itself may be involved in mediating drug resistance as well as in some tumor immune response modulation. Some of that's not clearly understood, I believe, right now. But certainly, preclinical data suggests that the drug may be effective in preclinical models and may also be effective in combination with chemotherapy and potentially with immune-modulating agents as well. So this particular study, as you said, was an open-label, randomized phase 2 study in which patients with pancreatic cancer were randomized 2:1 in favor of the elraglusib plus GMP—gemcitabine and nab-paclitaxel—versus the chemotherapy alone. And upon completion of the study, which is not right now, median overall survival was the primary end point, but there are a number of other end points which I'll talk about in just a moment. But the sample size was planned to be around 207 patients. The primary analysis included 155 patients in the combination arm versus 78 patients in the gemcitabine/nab-paclitaxel arm. Overall, the 1-year overall survival rate was 44.1% for the patients in the elraglusib-containing arm versus 23.0% in the patients receiving gemcitabine/nab-paclitaxel only. When they look at the median overall survival, it was 9.3 months for the experimental arm versus 7.2 months for chemotherapy alone. So put another way, there's around a 37% reduction in the risk of death with the use of this combination arm. The treatment was overall well-tolerated. There were some issues with grade 1 to 2 transient visual impairment in a large proportion of the patients. The most common treatment-related adverse effects with the elraglusib/GMP combination was transient visual impairment, which affected around 60% of the patients. Most of the more serious treatment-related adverse events included neutropenia, anemia, and fatigue in 50%, 25%, and 16% of the patients, respectively. So the early results from this study show a significant benefit for 1-year overall survival and for median overall survival with, as I mentioned above, a significant reduction in the risk of death. The authors went on to mention that the median overall survival for the control arm in this study is somewhat lower than in other comparable trials, but they think that this may be related to a more advanced disease burden in this particular study. Of interest to me was that right now: there is no apparent difference in progression-free survival between the 2 arms of this study. The authors described this as potentially indicating that this may be related in some way to immune modulation and immune effects on the tumor, which, if I'm completely honest, I don't totally understand. And so, the improvement in overall survival, as far as I can see at the moment, is not matched by an improvement in progression-free survival. So I think we probably need to wait for more time to elapse to see what happens with the study. And so, I think it certainly is an interesting study, and the results are intriguing, but I think it's probably a little early for it to actually shift the treatment paradigm in this disease. Dr. Hamilton: Fantastic. I think we've been waiting for advances in pancreatic cancer for a long time, but this, not unlike others, we learn more and then learn more we don't realize, so. Dr. Sweetenham: Right. Let's shift gears at this point and talk about a couple of other abstracts in kind of a very different space. Let's start out with symptom management for older adults with cancer. We know that undertreated symptoms are common among the older patient population, and Abstract 11002 reported on a randomized trial that demonstrated the effects of remote monitoring for older patients with cancer in terms of kind of symptoms and so on. Can you tell us a little bit about this study and whether you think this approach will potentially improve care for older patients? Dr. Hamilton: Yeah, I really liked this abstract. It was conducted through the Veterans Affairs, and it was based in California, which I'm telling you that because it's going to have a little bit of an implication later on. But essentially, adults that were 75 years or older who were Medicare Advantage beneficiaries were eligible to participate. Forty-three clinics in Southern California and Arizona, and patients were randomized either into a control group of usual clinic care alone, or an intervention group, which was usual care plus a lay health worker-led proactive telephone-based weekly symptom assessment, and this was for 12 months using the validated Edmonton Symptom Assessment System. So, there was a planned enrollment of at least 200 patients in each group. They successfully met that. And this lay health worker reviewed assessments with a physician assistant, who conducted follow-up for symptoms that changed by 2 points from a prior assessment or were rated 4 or greater. So almost a triage system to figure out who needed to be reached out to and to kind of work on symptoms. What I thought was fantastic about this was it was very representative of where it enrolled. There were actually about 50% of patients enrolled here that were Hispanic or Latinos. So some of our underserved populations and really across a wide variety of tumor types. They found that the intervention group had 53% lower odds of emergency room use, 68% lower odds of hospital use than the control group. And when they translated this to actual total cost of care, this was a savings of about $12,000 U.S. per participant and 75% lower odds of a death in an acute care facility. So I thought this was really interesting for a variety of reasons. One, certainly health care utilization and cost, but even more so, I think any of our patients would want to prevent hospitalizations and ER visits. Normally, that's not a fantastic experience having to feel poorly enough that you're in the emergency room or the hospital. And really showing in kind of concrete metrics that we were able to decrease this with this intervention. In terms of sustainability and scalability, I think the question is really the workforce to do this. Obviously, you know, this is going to take dedicated employees to have the ability to reach out to these patients, etc., but I think in value-based care, there's definitely a possibility of having reimbursement and having the funds to institute a program like this. So, definitely thought-provoking, and I hope it leads to more interventions. Dr. Sweetenham: Yeah, we've seen, over several years now, many of these studies which have looked at remote symptom monitoring and so on in this patient population, and many of them do show benefits for that in kinds of end points, not the least in this study being hospitalization and emergency room avoidance. But I think the scalability and personnel issue is a huge one, and I do wonder at some level whether we may see some AI-based platforms coming along that could actually help with this and provide interactions with these patients outside of actual real people, or at least in combination with real people. Dr. Hamilton: Yeah, that's a fantastic point.  So let's talk a little bit about clinical trials. So eligibility assessment for oncology clinical trials, or prescreening, really relies on manual review of unstructured clinical notes. It's time-consuming, it's prone to errors, and Abstract 1508 reported on the final analysis of a randomized trial that looked at the effect of human-AI teams prescreening for clinical trial eligibility versus human-only or AI-only prescreening. So give us more good news about AI. What did the study find? Dr. Sweetenham: Yeah, this is a really, a really interesting study. And of course, any of us who have ever been involved in clinical trials will know that accrual is always a problem. And I think most centers have attempted, and some quite successfully managed to develop prescreening programs so that patients are screened by a health care provider or health care worker prior to being seen in the clinic, and the clinical investigator will then already know whether they're going to be eligible for a trial or not. But as you've already said, it's a slow process. It's typically somewhat inefficient and requires a lot of time on the part of the health care workers to actually do this in a successful way. And so, this was a study from Emory University where they took three models of ways in which they could assess the accuracy of the prescreening of charts for patients who are going to be considered for clinical trials. One of these was essentially the regular way of having two research coordinators physically abstract the charts. The second one was an AI platform which would extract longitudinal EHR data. And then the third one was a combination of the two. So the AI would be augmented by the research coordinator or the other way around. As a gold standard, they had three independent oncology reviewers who went through all of these charts to provide what they regarded as being the benchmark for accuracy. In a way, it's not a surprise to me because I think that a number of other systems which have used this combination of human verification of AI-based tools, it actually ultimately concluded that the combination of the two in terms of chart accuracy was for the most part better than either one individually, either the research coordinator or the AI alone. So I'll give you just a few examples of where specifically that mattered. The human plus AI platform was more accurate in terms of tumor staging, in terms of identifying biomarker testing and biomarker results, as well as biomarker interpretation, and was also superior in terms of listing medications. There are one or two other areas where either the AI alone was somewhat more accurate, but the significant differences were very much in favor of a combination of human + AI screening of these patient charts. So, in full disclosure, this didn't save time, but what the authors reported was that there were definite efficiency gains, and presumably this would actually become even more improved once the research coordinators were somewhat more comfortable and at home with the AI tool. So, I thought it was an interesting way of trying to enhance clinical trial accrual up front by this combination of humans and technology, and I think it's going to be interesting to see if this gets adopted at other centers in the future. Dr. Hamilton: Yeah, I think it's really fascinating, all the different places that we can be using AI, and I love the takeaway that AI and humans together are better than either individually. Dr. Sweetenham: Absolutely.  Thanks once again, Dr. Hamilton, for sharing your insights with us today and for all of the incredible work you did to build a robust program. And also, congratulations on what was, I think, a really remarkable ASCO this year, one of the most exciting for some time, I think. So thank you again for that. Dr. Hamilton: Thanks so much. It was really a pleasure to work on ASCO 2025 this year. Dr. Sweetenham: And thank you to our listeners for joining us today. You'll find links to all the abstracts we discussed today in the transcript of this episode. Be sure to catch up on all of our coverage from the Annual Meeting. You can catch up on my daily reports that were published each day of the Annual Meeting, featuring the key science and innovations presented. And we'll have wrap-up episodes publishing in June, covering the full spectrum of malignancies from ASCO25. If you value the insights you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose    Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Welcome to the Celestial Insights Podcast, the show that brings the stars down to Earth! Each week, astrologer, coach, and intuitive Celeste Brooks of Astrology by Celeste will be your guide. Her website is astrologybyceleste.com.  

In this episode of Grow a Small Business, host Troy Trewin speaks with Matthew Whyatt, Managing Director of Tech Torque Systems. Matthew shares his entrepreneurial journey, scaling a previous business to 70 employees before intentionally transitioning to a leaner, more focused team of six at Tech Talk, specializing in B2B marketing for SaaS and tech companies.   He discusses the power of long-term strategy, the impact of personal branding, and the growing effectiveness of hyper-personalized marketing. With revenue projected to exceed $1 million, Matthew attributes much of the company's success to a disciplined marketing approach, robust systems, and clearly defined processes. He also opens up about the realities of cash flow management, the importance of professional development, and the enduring value of mentorship in sustaining business growth. Why would you wait any longer to start living the lifestyle you signed up for? Balance your health, wealth, relationships and business growth. And focus your time and energy and make the most of this year. Let's get into it by clicking here. Troy delves into our guest's startup journey, their perception of success, industry reconsideration, and the pivotal stress point during business expansion. They discuss the joys of small business growth, vital entrepreneurial habits, and strategies for team building, encompassing wins, blunders, and invaluable advice. And a snapshot of the final five Grow A Small Business Questions: What do you think is the hardest thing in growing a small business? According to Matthew Whyatt, the hardest part of growing a small business is avoiding distractions and staying focused on what truly drives long-term success. He stresses the temptation of chasing "shiny objects"—the latest tools, trends, or business ideas—that can derail progress. Instead, he believes in the importance of discipline, consistency, and nurturing the core business strategy. Using the metaphor of letting the oak tree grow from the acorn you planted, he emphasizes the need to water, tend, and build structure and systems around the business rather than relying on short-term tactics or quick wins. What's your favorite business book that has helped you the most? Matthew Whyatt mentions several impactful business books, but one of his favorites that has helped him the most is The Greatest Salesman in the World by Og Mandino. He appreciates it for its powerful lessons wrapped in a fable format. He also highlights The Goal by Eliyahu Goldratt, which offers valuable insights into process thinking and business systems, and says that thinking of a business like a manufacturing process can significantly improve throughput and efficiency. These books have deeply influenced his approach to sales, systems, and business strategy. Are there any great podcasts or online learning resources you'd recommend to help grow a small business? Matthew Whyatt recommends several valuable podcasts and online learning resources for growing a small business. He highlights Dale Beaumont's Business Blueprint as particularly impactful, noting its structured, systems-focused approach and strong community of business owners. He also mentions learning a lot from thought leaders like Alex Hormozi and Neil Patel, especially around marketing and personal branding. In terms of podcasts, he recommends checking out Nathan Latka's podcast, which focuses on SaaS businesses and digs deep into financials and growth strategies—ideal for those in the tech and software space. What tool or resource would you recommend to grow a small business? Matthew Whyatt recommends your calendar as the most powerful tool for growing a small business. He emphasizes the importance of scheduling tasks with discipline and structure to maintain consistency and productivity. In addition, he suggests exploring AppSumo to find lifetime deals on useful business tools, helping reduce the burden of monthly subscriptions while still accessing high-quality software for marketing, automation, and operations. These resources, combined with disciplined execution, can significantly enhance small business growth. What advice would you give yourself on day one of starting out in business? Matthew Whyatt's advice to his younger self on day one of starting out in business would be: “It's all going to be okay.” This simple yet powerful message reflects his belief in trusting the journey, staying resilient through challenges, and focusing on long-term growth rather than immediate outcomes. It encapsulates the importance of patience, perspective, and perseverance in entrepreneurship. Book a 20-minute Growth Chat with Troy Trewin to see if you qualify for our upcoming course. Don't miss out on this opportunity to take your small business to new heights! Enjoyed the podcast? Please leave a review on iTunes or your preferred platform. Your feedback helps more small business owners discover our podcast and embark on their business growth journey.     Quotable quotes from our special Grow A Small Business podcast guest: Success is planting the acorn, nurturing it, and letting the oak tree thrive with systems and structure — Matthew Whyatt True success is the freedom to wake up and do what you love every single day — Matthew Whyatt Avoid the short-term sugar hit; long-term success is built on consistency and discipline — Matthew Whyatt  

We're diving deep into the world of zero-torque putters — the techy flatsticks designed to stay square and keep your stroke stable. After tons of testing, we're ranking our Top 10 Zero-Torque Putters of the year! From full-on futuristic to surprisingly traditional, these are the ones that actually perform on the greens.

Andy Edstrom unpacks whether Bitcoin is truly the last asymmetric bet for companies, diving into MicroStrategy's model, capital structure risks, and Bitcoin's rising institutional role. IN THIS EPISODE YOU'LL LEARN: 00:00 - Intro 03:40 - Why Michael Saylor calls Bitcoin a lifeline for “zombie companies” 05:20 - How Bitcoin's returns compare to traditional assets over the last decade 07:10 - The strategic and accounting evolution enabling Bitcoin treasury allocations 12:00 - MicroStrategy's premium-to-NAV strategy and its replicability 15:40 - Risks and rewards of BTC-backed leverage and convertible notes 18:05 - The logic behind “torque” metrics in Bitcoin-financed capital structures 21:10 - If preferred shares like STRK and STRF are innovative or dangerous 23:05 - Wall Street's changing views on Bitcoin-leveraged equity plays 27:20 - Legal and governance hurdles in corporate Bitcoin adoption 29:10 - What a BTC-heavy balance sheet should do during a major drawdown Disclaimer: Slight discrepancies in the timestamps may occur due to podcast platform differences. BOOKS AND RESOURCES Andy's X Account. Microstrategy Shareholders' Meeting: Q1 2025 Earnings Call. Michael Saylor's speech at Strategy World: Bitcoin for Corporations 2025 Keynote Speech. Check out all the books mentioned and discussed in our podcast episodes ⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠. Enjoy ad-free episodes when you subscribe to our ⁠⁠⁠⁠⁠⁠Premium Feed⁠⁠⁠⁠⁠⁠. NEW TO THE SHOW? Join the exclusive ⁠⁠⁠TIP Mastermind Community⁠⁠⁠ to engage in meaningful stock investing discussions with Stig, Clay, Kyle, and the other community members. Follow our official social media accounts: ⁠⁠⁠X (Twitter)⁠⁠⁠ | ⁠⁠⁠LinkedIn⁠⁠⁠ | | ⁠⁠⁠Instagram⁠⁠⁠ | ⁠⁠⁠Facebook⁠⁠⁠ | ⁠⁠⁠TikTok⁠⁠⁠. Check out our ⁠⁠⁠Bitcoin Fundamentals Starter Packs⁠⁠⁠. Browse through all our episodes (complete with transcripts) ⁠⁠⁠here⁠⁠⁠. Try our tool for picking stock winners and managing our portfolios: ⁠⁠⁠TIP Finance Tool⁠⁠⁠. Enjoy exclusive perks from our ⁠⁠⁠favorite Apps and Services⁠⁠⁠. Get smarter about valuing businesses in just a few minutes each week through our newsletter, ⁠⁠⁠The Intrinsic Value Newsletter⁠⁠⁠. Learn how to better start, manage, and grow your business with the ⁠⁠⁠best business podcasts⁠⁠⁠. SPONSORS Support our free podcast by supporting our ⁠⁠⁠sponsors⁠⁠⁠: SimpleMining Hardblock AnchorWatch Fundrise DeleteMe CFI Education Vanta The Bitcoin Way Onramp Indeed Shopify HELP US OUT! Help us reach new listeners by leaving us a ⁠⁠⁠rating and review⁠⁠⁠ on ⁠⁠⁠Spotify⁠⁠⁠! It takes less than 30 seconds, and really helps our show grow, which allows us to bring on even better guests for you all! Thank you – we really appreciate it! Support our show by becoming a premium member! https://premium.theinvestorspodcast.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://theinvestorspodcastnetwork.supportingcast.fm